Evidence map›Paper›PMID 27881673›Full record

ArticleThe Journal of biological chemistry2017

Sortilin 1 Modulates Hepatic Cholesterol Lipotoxicity in Mice via Functional Interaction with Liver Carboxylesterase 1.

Jibiao Li, Yifeng Wang, David J Matye, Hemantkumar Chavan, Partha Krishnamurthy, Feng Li, Tiangang Li

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Cholesterol and bile acid-mediated regulation of autophagy in fatty liver diseases and atherosclerosis.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2018
    Review
  15. Mouse models of gallstone disease.Current opinion in gastroenterology · 2018
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jibiao LiFrom the Department of Pharmacology, Toxicology and Therapeutics, Kansas University Medical Center, Kansas City, Kansas 66160 and.
Yifeng WangFrom the Department of Pharmacology, Toxicology and Therapeutics, Kansas University Medical Center, Kansas City, Kansas 66160 and.
David J MatyeFrom the Department of Pharmacology, Toxicology and Therapeutics, Kansas University Medical Center, Kansas City, Kansas 66160 and.
Hemantkumar ChavanFrom the Department of Pharmacology, Toxicology and Therapeutics, Kansas University Medical Center, Kansas City, Kansas 66160 and.
Partha KrishnamurthyFrom the Department of Pharmacology, Toxicology and Therapeutics, Kansas University Medical Center, Kansas City, Kansas 66160 and.
Feng Lithe Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030.
Tiangang LiFrom the Department of Pharmacology, Toxicology and Therapeutics, Kansas University Medical Center, Kansas City, Kansas 66160 and tli@kumc.edu.
University Medical Center · USUniversity of Kansas Medical Center · USBaylor College of Medicine · US

Funding

THE ROLE OF HUMAN PXR IN ANTI-TUBERCULOSIS DRUG-INDUCED LIVER INJURYP20RR021940 · NCRR · UNIVERSITY OF KANSAS MEDICAL CENTER · PI COPPLE, BRYAN L · 2006 to 2011
$12.1M
Nuclear Receptors in Liver Health and DiseaseP20GM103549 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI JAESCHKE, HARTMUT W. · 2012 to 2015
$8.1M
Pilot Grants ProgramP30GM118247 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI JAESCHKE, HARTMUT W. · 2016 to 2020
$5.5M
The role of hepatic Sortlin 1 in diabetic dyslipidemiaR01DK102487 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI LI, TIANGANG · 2014 to 2018
$1.6M
NCRR NIH HHS P20 RR021940NIDDK NIH HHS R01 DK102487NIGMS NIH HHS P20 GM103549NIGMS NIH HHS P30 GM118247
6 · The paper itself

Abstract

The liver plays a key role in cholesterol metabolism. Impaired hepatic cholesterol homeostasis causes intracellular free cholesterol accumulation and hepatocyte injury. Sortilin 1 (SORT1) is a lysosomal trafficking receptor that was identified by genome-wide association studies (GWAS) as a novel regulator of cholesterol metabolism in humans. Here we report that SORT1 deficiency protected against cholesterol accumulation-induced liver injury and inflammation in mice. Using an LC-MS/MS-based proteomics approach, we identified liver carboxylesterase 1 (CES1) as a novel SORT1-interacting protein. Mechanistic studies further showed that SORT1 may regulate CES1 lysosomal targeting and degradation and that SORT1 deficiency resulted in higher liver CES1 protein abundance. Previous studies have established an important role of hepatic CES1 in promoting intracellular cholesterol mobilization, cholesterol efflux, and bile acid synthesis. Consistently, high cholesterol atherogenic diet-challenged Sort1 knock-out mice showed less hepatic free cholesterol accumulation, increased bile acid synthesis, decreased biliary cholesterol secretion, and the absence of gallstone formation. SORT1 deficiency did not alter hepatic ceramide and fatty acid metabolism in high cholesterol atherogenic diet-fed mice. Finally, knockdown of liver CES1 in mice markedly increased the susceptibility to high cholesterol diet-induced liver injury and abolished the protective effect against cholesterol lipotoxicity in Sort1 knock-out mice. In summary, this study identified a novel SORT1-CES1 axis that regulates cholesterol-induced liver injury, which provides novel insights that improve our current understanding of the molecular links between SORT1 and cholesterol metabolism. This study further suggests that therapeutic inhibition of SORT1 may be beneficial in improving hepatic cholesterol homeostasis in metabolic and inflammatory liver diseases.

Indexed as

Adaptor Proteins, Vesicular TransportAnimalsCarboxylic Ester HydrolasesCells, CulturedChemical and Drug Induced Liver InjuryCholesterolFemaleHepatocytesHep G2 CellsHumansInflammationMaleMiceMice, Inbred C57BLMice, KnockoutRNA, Small InterferingAdaptor Proteins, Vesicular Transportcarboxylesterase 1, mouseCarboxylic Ester HydrolasesCholesterolRNA, Small InterferingSortilinbile acidCES1CYP7A1fatty liverFXRhypercholesterolemialipid metabolismliver injurynuclear receptorprotein trafficking (Golgi)steatohepatitis

Identifiers

PMID27881673
PMCPMC5217674
OpenAlexW2551450955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.